2021Q1 Cell Therapy Inventory: Global financing totals over US$3.7 billion, 8 companies IPO listing

，、、、、HIV，。

PharmaInvest，202140（IPO），37。

， T，37%，（19%）、NK（14%）、（TIL，9%）。，、、（DC）、。，T，23。，12。

2021Q1（）（）。：，，。，。

，T。T，CAR-T。，5CAR-T，。，CAR-T，、。，2021Q1，，CAR-T。

，312，Science，CAR-T。synNotch，CAR-T，。HER2，、HER2，HER2。

324，Science Translational MedicineLentigenCD19/CD20/CD22CAR-T。，，。。

：7IPO，Sana

，30，7IPO，Sana BiotechnologyIPO6.

2021Q1

， 2018 Sana202067，，。

Why is Sana so sucking money? 1) From the perspective of pipeline, Sana is in the two hot tracks of gene therapy and cell therapy.

In addition to the eye-catching Sana, CARISMA Therapeutics was active in Q1 and involved two financing incidents.

CARISMA is an American biopharmaceutical company dedicated to the development of a differentiated proprietary cell therapy platform for engineered macrophages.

On March 18, CARISMA announced that it has completed the first patient administration of CT-0508 in a phase I multi-center clinical trial (NCT04660929).

Domestic: CAR-T and TIL are the hottest, emerging technologies attract attention

There were 10 cell therapy-related financing events in the first quarter of China.

In addition to mainstream T cell therapy, some emerging technologies have also gained attention, such as Red-Cell Therapeutics (RCT).

Overview of domestic financing in the field of cell therapy in 2021Q1

As a branch of cell therapy technology, RCT uses red blood cells as the main drug carrier and can be used for the treatment of various diseases such as cancer, immune and metabolic diseases, and infectious diseases.

The RCT engineered using stem cells was first pioneered by the American biologic company Rubius Therapeutics.

RTX-240 is an allogeneic spot-type cell therapy designed to present hundreds of thousands of costimulatory molecules 4-1BBL and IL-15TP at the same time, thereby activating and expanding NK cells and memory T cells, enhancing the body’s immunity to kill Tumor cells.

Giants: CAR-NK "True Fragrance"

In addition to the financing of a large number of cell therapy companies, in the first quarter, there were three pharmaceutical giants that strengthened their layout in this field through transaction cooperation.

2021Q1 Cell Therapy Field Giants Transaction Cooperation

On January 28, Artiva Biotherapeutics, an American biotechnology company dedicated to the development of anti-cancer NK cell therapies, announced that it has signed a global exclusive cooperation and licensing agreement with Merck & Co.

Artiva has been active in the past two years.

Although compared with T cell therapy, NK cell therapy is newer, but it has unique advantages: 1) Pan-specific killing effect makes the anti-tumor spectrum of NK cells unrestricted; 2) Good safety, NK cells will not cause cytokines Release syndrome or graft-versus-host disease (a common side effect of T cell therapy); 3) It is particularly suitable for spot-type therapy, etc.

-------

Cellular immunotherapy is one of the most popular tumor treatment research directions in recent years, in which T cell therapy occupies a dominant position, but other cell therapies, such as NK cells, macrophages, myeloid cells, red blood cell therapy, and other new technologies are also constantly developing.

Stem cell therapy is another important type in the field of cell therapy, and it is also a very promising anti-cancer strategy.
Scientific research has found that stem cells, especially mesenchymal stem cells, can effectively deliver anti-tumor drugs.
Mesenchymal stem cells can also slow the progression of cancer by regulating the immune components in the tumor microenvironment.
In addition, stem cells may function as anti-cancer vaccines and can also be used to develop universal CAR-T/NK cell therapies, which has great potential.

In summary, the field of cell therapy is still "full-blown".
In 2021Q1, there are still many companies that have completed financing, 8 companies have IPOs, and pharmaceutical giants are still increasing investment in layout.
Looking forward to more innovative cell therapies from the laboratory to the clinic in the near future, benefiting patients.